R&D News | pharmaphorum

News

Genesis raises $200m for AI drug discovery engine

Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million

News

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe

News

OneOncology taps Verily for clinical trials platform

OneOncology has joined forces with Verily to speed up and improve the efficiency of clinical trials run through its network of independent cancer treatment centres in the

News

Seagen posts breast cancer win ahead of Pfizer takeover

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a

News

Abcuro raises $155m for KLRG1 drug trial

Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi

News

Boehringer preps phase 3 for dual-action obesity drug

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.

Genesis raises $200m for AI drug discovery engine

Trial backs use of Cabometyx, Tecentriq in prostate cancer

OneOncology taps Verily for clinical trials platform

Seagen posts breast cancer win ahead of Pfizer takeover

Abcuro raises $155m for KLRG1 drug trial

Boehringer preps phase 3 for dual-action obesity drug

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks